NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 15 March 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Peter Jackson (Chair) Present for all items
2. Dr Paul Arundel (Vice Chair) Present for all items
3. Annett Blochberger Present for all items
4. Emtiyaz Chowdhury Present for all items
5. Dr Prithwiraj Das Present for all items
6. Stuart Davies Present for all items
7. Sarah Davis Present for all items
8. Tina Garvey Present for all items
9. Professor Jonathan Ives Present for all items
10. Stuart Mealing Present for all items
11. Sara Payne Present for all items
12. Dominic Pivonka Present for all items
13. Angharad Shambler Present for all items
14. Professor Ed Wilson Present for all items

NICE staff (key players) present

Jasdeep Hayre, Associate Director Present for all items

Celia Mayers, Project Manager Present for all items

Caron Jones, Health Technology Assessment Adviser Present for all items

Anne Murray-Cota, Health Technology Assessment Analyst Present for all items

Olivia Waring, Senior Medical Editor Items 1.1 to 4.2

Emma Gordon, Coordinator, Corporate Office Items 1.1 to 4.1.3

Leah Kelly, Administrator, TA Present for all items

Liam Murray, Administrator, COT Present for all items

NICE staff (observers) present

Sarah Wilkes, Technical Analyst, Commercial Liaison Present for all items

Milena Wobbe, Technical Analyst, CMA Present for all items

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Willem Witlox, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Clinical, Patient & NHS England experts present

Dr Shobhit Baijal, Consultant Medical Oncologist, Clinical expert nominated by BTOG, Items 1.1 to 4.1.3

Peter Clark, NHSE CDF clinical lead Present for all items

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Peter Jackson, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Anthony Williams, Carrie Gardner, Philip Beales and Dr Shehla Mohammed.

### News and announcements

* 1. The chair reminded committee members of the Technology Appraisals / Highly Special Technologies Committee Away Day happening on Monday 22 May 2023.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 9 February 2023

### Evaluation of selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer [ID4056]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Emtiyaz Chowdhury declared a non-financial professional interest as he is employed by Parexel who provides services to the manufacturer. He has not been involved in any specific activities related to the technology under consideration. It was agreed that his declaration would not prevent Emtiyaz from participating in discussions on this evaluation.
* Dr Prithwiraj Das declared a non-financial professional interest as he works in pharmaceutical market access as Founding Director of G2PR Ltd. He has not worked on these products, indications, or possible comparators in the past. It was agreed that his declaration would not prevent Dr Das from participating in discussions on this evaluation.
* Dominic Pivonka declared financial interests as his employer (AbbVie) has treatments in development (Phase 1-3) for non-small-cell lung cancer including one that has been selected for appraisal through the NICE technology appraisals process (Telisotuzumab vedotin). This treatment is for c-MET overexpressed, EGFR wild-type, which is not in the same target population as the indication for selpercatinib, and so not a possible competitor or comparator. It was agreed that his declaration would not prevent Dominic from participating in discussions on this evaluation.
* Dr Shobhit Baijal declared a financial interest as he has received honoraria from Lilly and Roche (who make pralsetinib) for consultancy work. It was agreed that his declaration would not prevent Dr Baijal from providing expert advice to the committee.
* No further interests were declared for this evaluation.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Annett Blochberger, Jonathan Ives and Ed Wilson.
  1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11012>

1. Date of the next meeting
   1. Please note that the meeting initially scheduled for Thursday April 6 2023 has been cancelled as no topics have been scheduled.
   2. The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Wednesday 10 May 2023 and will start promptly at 10:00am.